Amydis Inc. announced that patient enrollment in underway for a phase 1/2a trial to evaluate AMDXP-2011P, a retinal imaging agent that targets protein biomarkers in patients with Parkinson’s disease and ALS.
According to a company press release, the “retinal tracer” is a fluorescent, nonradioactive imaging agent — designed to be used with currently available ocular imaging devices — that detects and quantifies deposits of alpha synuclein (ASYN) in patients with PD and TAR DNA-binding protein 43 (TDP-43) in patients with ALS. There are currently no approved